Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study
about
Acute lymphoblastic leukaemiaChemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemiaCollagen XVIII mutation in Knobloch syndrome with acute lymphoblastic leukemiaDrugging the unfolded protein response in acute leukemiasTargeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignanciesNovel agents and biomarkers for acute lymphoid leukemiaRedefining ALL classification: toward detecting high-risk ALL and implementing precision medicineA health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigmQuality assurance of RNA expression profiling in clinical laboratoriesAntigen-based immunotherapy for the treatment of acute lymphoblastic leukemia: the emerging role of blinatumomabCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaAdvancements in the treatment of pediatric acute leukemia and brain tumor - continuous efforts for 100% cureChildhood acute lymphoblastic leukemia: Integrating genomics into therapyCD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemiaPrognostification of ALL by CytogeneticsHow I treat acute lymphoblastic leukemia in older adolescents and young adultsRole of ABL family kinases in cancer: from leukaemia to solid tumoursMLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonismSubdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy.High-risk childhood acute lymphoblastic leukemiaThe Eleventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Ponte di Legno, Italy, 6-7 May 2009.Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemia.Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013.Childhood B-acute lymphoblastic leukemia: a genetic update.Outcomes for children and adolescents with cancer: challenges for the twenty-first century.Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes.Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report.Cardiovascular disease in adult survivors of childhood cancer.Declining childhood and adolescent cancer mortalityAbsence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemiaActivation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia.Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.Immature B-cell progenitors survive oncogenic stress and efficiently initiate Ph+ B-acute lymphoblastic leukemiaThe Biology and Targeting of FLT3 in Pediatric Leukemia.Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment.Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group.Use of appropriate initial treatment among adolescents and young adults with cancer.Using functional genomics to overcome therapeutic resistance in hematological malignancies.
P2860
Q24602387-1A1E0773-BF6D-4F07-8910-1CFC1F476D6CQ24622397-3959453F-5EB5-472C-91DF-3120E8C8E5E6Q24622648-DFF56BFC-619B-46B2-83A9-8BBB5AEE95D7Q26801114-D0C95386-CB2B-4731-B2BA-64ED45EF08B5Q26829652-1517A537-FB2B-46D0-9FF3-DC8E961D587EQ26829775-C689DF4A-783D-42BA-8410-5E3DACA6BA81Q26864460-B5C145C4-4D5B-4AE6-AF9C-938B194A3E52Q26866379-83E6CA00-AB4E-4B02-9F5E-3B2A6C3EBDB9Q26866455-CF991543-C06D-46DC-84B5-C13DB0B3C505Q27013710-A866966B-9D76-40A8-9AE6-1A8C6E1163E7Q27025242-6B584B53-9ADA-4CC0-B2AF-E8FBC2EEB1E4Q27027799-CA924C98-B30B-4CEF-B17E-C4A2D06EA330Q28080463-53AF45B0-7BB3-4035-ADEB-233496B1FFABQ28084879-65E5C9B0-D848-4CFE-A97D-D094F628DC0EQ28087446-1D3D7FC5-FBD2-41D1-AE56-2CA1D8DD208DQ28087589-9E0E608C-4746-436E-B61C-0D314D812C55Q28396643-8E6D48F5-5162-43F3-B290-4F8F400D15FFQ28658170-F1DCF41F-FF84-4611-A4F0-E79342FB8C43Q33395138-A3B35658-2C7E-4151-ACE5-0175DC33746BQ33622837-507EDEA4-2647-4D60-B347-657FD6137A31Q33636082-B423F6CF-4F95-49BF-B67E-DA4BC0316654Q33711119-36448D2F-F23A-423C-8438-943A4FD8A515Q33746736-2DCF5C04-87C0-4F36-8AF0-CAB270A98931Q33762835-42866F14-1889-4716-9627-6641EDDDA972Q33777616-674D71D3-0E42-454B-9B2C-BC0B5EFE481DQ33897659-90E9F496-58E7-49EF-B831-87545750A1E7Q33915980-A3CF49F8-F545-4F63-89B9-7BE087522EBEQ34003323-FD952CC1-0185-4FC2-AF1A-DDC7C24E99E0Q34042984-21F15ABA-908A-4C16-BBDF-0C8733B58BD1Q34060045-7895CECD-9ACF-4684-884F-E3122303294BQ34131813-898F1D1E-C192-4476-AA2B-B5490AC9F97AQ34168766-ADBC450A-282D-48A7-88A7-DABED5B08085Q34172033-F9462D77-39BE-4030-B57B-1200B03617C7Q34193548-45F1D11F-2829-4CFA-8D5F-3B1EACE8906DQ34229555-83457186-372A-4917-863F-A897A0E28104Q34314927-A2BBE2E2-F299-4461-AF62-4ECE2962209FQ34325815-E6470D8C-58BE-4583-9C79-6581A60852F1Q34343785-CD7B511C-7B06-4269-BF1B-D84DE600565BQ34354175-29A08121-304C-4DDD-93FC-835F0235119DQ34401328-DD73BD3C-E30C-4717-8250-241ACFBE77A8
P2860
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Improved early event-free surv ...... hildren's oncology group study
@en
Improved early event-free surv ...... ildren's oncology group study.
@nl
type
label
Improved early event-free surv ...... hildren's oncology group study
@en
Improved early event-free surv ...... ildren's oncology group study.
@nl
prefLabel
Improved early event-free surv ...... hildren's oncology group study
@en
Improved early event-free surv ...... ildren's oncology group study.
@nl
P2093
P2860
P50
P356
P1476
Improved early event-free surv ...... hildren's oncology group study
@en
P2093
Andrew Carroll
Bruce Camitta
Chenguang Wang
Dean Jorstad
Harland Sather
Laura Burden
Meenakshi Devidas
Michael J Borowitz
Michael Trigg
Naomi Winick
P2860
P304
P356
10.1200/JCO.2008.21.2514
P407
P577
2009-10-05T00:00:00Z